
Distinguish among FDA submission pathways and evaluate how classification, risk, clinical evidence, newer technologies, and available submission programs affect regulatory planning and market authorization.
Includes live access & recording
Medical devices entering the U.S. market, or undergoing substantial changes, may require different FDA pathways depending on classification, risk, intended use, and the evidence needed for review. The 510(k), De Novo, and PMA processes address different market authorization circumstances, while an Investigational Device Exemption (IDE) supports investigational device use before submission when clinical data are required. Selecting and understanding the applicable pathway directly affects development and submission planning.
This webinar examines practical considerations across the 510(k), De Novo, PMA, and IDE processes, including substantial equivalence, higher-risk devices requiring clinical evidence, and recent 510(k) modifications intended to accommodate newer technology or increased safety.
The discussion also addresses the Q-Submission process, Breakthrough and STeP considerations, Machine Learning and Artificial Intelligence features that can add submission complexity, and post-market requirements.
Develop a clearer basis for distinguishing among 510(k), De Novo, PMA, and IDE pathways based on device classification, risk, substantial equivalence, and clinical evidence considerations. Understanding these distinctions helps regulatory and product teams recognize how the applicable route affects submission planning and FDA review before commercialization in the United States.
Account for Newer Technologies and Submission Options. Strengthen awareness of factors that can complicate or modify traditional submission planning, including newer technology, increased safety, Q-Sub interactions, Breakthrough and STeP considerations, and Machine Learning or Artificial Intelligence features. This perspective helps teams evaluate how evolving device characteristics may affect the pathway and supporting evidence presented to FDA.
By the end of this session, participants will be equipped to recognize the applicable FDA pathway and plan the evidence needed for U.S. market authorization.
Distinguish among FDA medical device submission and review pathways.
Apply substantial equivalence principles to 510(k) clearance.
Recognize when De Novo classification fits lower-risk novel devices.
Understand PMA requirements and clinical evidence for higher-risk devices.
Plan Investigational Device Exemptions and clinical investigations.
Use Q-Submission, Breakthrough, and STeP programs in regulatory planning.
Address Machine Learning and Artificial Intelligence submission issues.
Prepare for post-market requirements following device authorization.
Focused areas that will strengthen how your organization selects and plans FDA submission pathways.
Compare 510(k), De Novo, PMA, and IDE routes based on classification, risk, intended use, and evidence needs.
Understand when higher-risk devices require clinical data and how an IDE supports investigational use before submission.
Use FDA interaction and expedited programs to shape submission strategy and review.
Anticipate how Machine Learning and Artificial Intelligence features add complexity to submissions.
A practical look at how device classification and evidence requirements influence FDA review and U.S. market authorization.
Professionals across regulatory, quality, development, and commercial functions involved in bringing medical devices to the U.S. market.
Senior Management in Devices, Combination Products
Quality Assurance Departments
Quality Control Departments
Research and Development Departments
Regulatory Affairs Departments
Medical Device Product Development Teams
Manufacturing Departments
Engineering Departments
Operations Departments
Production Departments
Marketing Departments
Consultants
Everyone tasked with product development, manufacturing, data analysis, or regulatory submission responsibilities
Medical devices entering the U.S. market, or undergoing substantial changes, may require different FDA pathways depending on classification, risk, intended use, and the evidence needed for review. The 510(k), De Novo, and PMA processes each address different market authorization circumstances, and an Investigational Device Exemption supports investigational use when clinical data are required.
Recent 510(k) modifications intended to accommodate newer technology or increased safety, together with the Q-Submission process and the Breakthrough and STeP programs, give device teams more options — and more decisions — when planning a submission. Machine Learning and Artificial Intelligence features can add further complexity to the evidence FDA expects.
This course focuses on understanding how device classification and evidence requirements influence FDA review and U.S. market authorization, from pathway selection through post-market requirements.
Don't miss this essential training on 510(k), De Novo, PMA, and IDE pathways for modern medical devices. Secure your spot now.